Novo Nordisk will acquire Calibrium LLC and MB2 LLC, two privately held biopharmaceutical research companies.
The two companies are based in Indiana, US, and Novo Nordisk’s acquisition will expand the company portfolio within diabetes and obesity.
Formed in 2013 and 2014, respectively, Calibrium and MB2 are focused on developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases. The acquisition will expand Novo Nordisk’s portfolio of projects and intellectual property rights within diabetes and obesity and provide a basis for expanding Novo Nordisk’s research presence in the US.
“We are always on the lookout for ways to strengthen our leadership position within therapeutic proteins. This research team has demonstrated world-class capabilities in protein design and created a project portfolio of innovative product leads that fit very well with our aspirations within diabetes and obesity,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.
The parties have agreed not to disclose the financial details of the transactions. The closing of the transaction is subject to US regulatory approval and is expected to occur during the third quarter of 2015.
Source: Novo Nordisk
